# Clinical Trials Data KIT - Document 54

# Detection of Methylated Reprimo in Plasma for Asymptomatic Gastric Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01774266

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Male or Female\n\* Age 40-70 y.o.\n\nExclusion Criteria:\n\n\* Gastric Cancer\n\* Dyspepsia\n\* Bleeding disorders",  
 "healthyVolunteers": true,  
 "sex": "ALL",  
 "minimumAge": "40 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "3000 population base study from rural area in south of Chile. This is area has one of the highest incidence of gastric cancer in the world (35/100.000).",

Question:  
Based on the following clinical trial information, would a patient with a KIT gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided clinical trial information, a patient's eligibility does not seem to be affected by a KIT gene mutation. The eligibility criteria outlined in the trial information mention inclusion and exclusion factors such as age range, gender, and the presence of certain conditions (gastric cancer, dyspepsia, and bleeding disorders). There is no mention of genetic mutations, including the KIT gene mutation, as part of the criteria. Therefore, from the information given, a patient with a KIT gene mutation would be eligible, provided they meet the other inclusion and exclusion criteria specified.